BusinessaTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)By Nasdaq OMXNov 27, 2017, 1:01 PM UTC
BusinessaTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate UpdateBy Nasdaq OMXNov 14, 2017, 9:06 PM UTC
BusinessaTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology PipelineBy Nasdaq OMXAug 14, 2017, 8:06 PM UTC
BusinessaTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational WebinarBy Nasdaq OMXMay 15, 2017, 12:03 PM UTC
BusinessaTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational WebinarBy Nasdaq OMXMay 15, 2017, 12:03 PM UTC
